CCDC61: A Potential Drug Target and Biomarker for diseases (G729440)

Target Name: CCDC61

NCBI ID: G729440

CCDC61

CCDC61: A Potential Drug Target and Biomarker for diseases

CDC61 (Coiled-coil domain-containing protein 61) is a protein that has been identified as a potential drug target and biomarker for various diseases. It is a member of the superfamily of transmembrane proteins, which are involved in various physiological processes in the cell. In this article, we will discuss the structure, function, and potential drug targets of CDC61, as well as its potential as a biomarker for diseases.

Structure and Function

CDC61 is a 61-kDa protein that is expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is characterized by a transmembrane domain and a cytoplasmic domain. The cytoplasmic domain is responsible for the protein's stability and functions as a scaffold. The transmembrane domain is involved in the protein's stability and functions as an intracellular signaling molecule.

CDC61 is involved in various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. The TGF-β pathway is a well-established target for many diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, CDC61 may be a potential drug target for these diseases.

CDC61 has been shown to play a role in the regulation of cell adhesion, which is a critical process in the development and maintenance of tissues and organs. Adhesion helps to maintain the integrity of tissues and is involved in various physiological processes, including embryonic development, tissue repair, and cancer progression. Therefore, targeting CDC61 may be a promising approach to treating diseases that are characterized by disrupted cell adhesion, such as cancer, neurodegenerative diseases, and autoimmune diseases.

CDC61 has also been shown to be involved in the regulation of cell signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell growth, survival, and angiogenesis, and is a potential target for many diseases. Therefore, targeting CDC61 may be a promising approach to treating diseases that are characterized by disrupted PI3K/Akt signaling, such as cancer, neurodegenerative diseases, and autoimmune diseases.

Potential Drug Targets

CDC61 has been shown to be a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Here are some of the potential drug targets for CDC61:

1. Cancer: CDC61 has been shown to play a role in the regulation of cell signaling pathways, including the PI3K/Akt signaling pathway. Therefore, targeting CDC61 may be a promising approach to treating cancer.
2. Neurodegenerative Diseases: CDC61 has been shown to play a role in the regulation of cell signaling pathways, including the PI3K/Akt signaling pathway. Therefore, targeting CDC61 may be a promising approach to treating neurodegenerative diseases.
3. Autoimmune Diseases: CDC61 has been shown to play a role in the regulation of cell signaling pathways, including the PI3K/Akt signaling pathway. Therefore, targeting CDC61 may be a promising approach to treating autoimmune diseases.

Biomarkers

CDC61 may also be used as a biomarker for diseases. Its expression and function have been shown to be involved in various signaling pathways, including the TGF-β pathway and the PI3K/Akt signaling pathway. Therefore, measuring the expression and function of CDC61 may be a promising approach to diagnosing and monitoring diseases associated with these signaling pathways.

Conclusion

In conclusion, CDC61 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its structure and function have been shown to be involved in various signaling pathways, including the TGF-β pathway and the PI3K/Akt signaling pathway. Therefore, targeting CDC61 may be a promising approach to treating diseases associated with these signaling pathways, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, measuring the expression and function of CDC61 may be

Protein Name: Coiled-coil Domain Containing 61

Functions: Microtubule-binding centrosomal protein required for centriole cohesion, independently of the centrosome-associated protein/CEP250 and rootletin/CROCC linker (PubMed:31789463). In interphase, required for anchoring microtubule at the mother centriole subdistal appendages and for centrosome positioning (PubMed:31789463). During mitosis, may be involved in spindle assembly and chromatin alignment by regulating the organization of spindle microtubules into a symmetrical structure (PubMed:30354798). Has been proposed to play a role in CEP170 recruitment to centrosomes (PubMed:30354798). However, this function could not be confirmed (PubMed:31789463). Plays a non-essential role in ciliogenesis (PubMed:31789463, PubMed:32375023)

The "CCDC61 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC61 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets